Evidence map›Paper›PMID 30406210›Full record

ArticleClinical and translational radiation oncology2019

Single dose partial breast irradiation using an MRI linear accelerator in the supine and prone treatment position.

K R Charaghvandi, T Van't Westeinde, S Yoo, A C Houweling, A Rodrigues, H M Verkooijen, M E P Philippens, B van Asselen, J K Horton, H J G D van den Bongard

Erratum issuedAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Adaptive radiotherapy for breast cancer.Clinical and translational radiation oncology · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

K R CharaghvandiDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
T Van't WesteindeDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
S YooDepartment of Radiation Oncology, Duke Cancer Center, Durham, United States.
A C HouwelingDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
A RodriguesDepartment of Radiation Oncology, Duke Cancer Center, Durham, United States.
H M VerkooijenImaging Division, University Medical Center Utrecht, Utrecht, The Netherlands.
M E P PhilippensDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
B van AsselenDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
J K HortonDepartment of Radiation Oncology, Duke Cancer Center, Durham, United States.
H J G D van den BongardDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Funding

Interdisciplinary Research Careers in Women's HealthK12HD043446 · NICHD · DUKE UNIVERSITY · PI AMUNDSEN, CINDY · 2002 to 2023
$9.6M
NICHD NIH HHS K12 HD043446
6 · The paper itself

Abstract

backgroundIn selected patients with early-stage and low-risk breast cancer, an MRI-linac based treatment might enable a radiosurgical, non-invasive alternative for current standard breast conserving therapy.

aimTo investigate whether single dose accelerated partial breast (APBI) to the intact tumor in both the prone and supine radiotherapy positions on the MRI-linac is dosimetrically feasible with respect to predefined coverage and organs at risk (OAR) constraints. MATERIAL &

methodsFor 20 patients with cTis or low-risk cT1N0M0 non-lobular breast carcinoma, previously treated with single dose preoperative APBI in the supine (n = 10) or prone (n = 10) position, additional intensity modulated radiotherapy plans with 7 coplanar beams in the presence of a 1.5T magnetic field were generated. A 20 Gy and 15 Gy dose was prescribed to the gross tumor and clinical target volume, respectively. The percentage of plans achieving predefined organ at risk (OAR) constraints, currently used in clinical practice, was assessed. Dosimetry differences between the prone versus supine approach and the MRI-linac versus clinically delivered plans were evaluated.

resultsAll MRI-linac plans met the coverage and predefined OAR constraints. The prone approach appeared to be more favorable with respect to the chest wall, and ipsilateral lung dose compared to the supine position. No dosimetric differences were observed for the ipsilateral breast. No treatment position was clearly more beneficial for the skin or heart, since dosimetry varied among parameters. Overall, the MRI-linac and clinical plans were comparable, with minor absolute dosimetric differences.

conclusionMRI-linac based single dose APBI to the intact tumor is a promising and a dosimetrically feasible strategy in patients with low-risk breast cancer. Preliminary OAR dosimetry favored the prone radiotherapy position.

Identifiers

PMID30406210
PMCPMC6215022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.